phenylacetic acid has been researched along with Chronic Illness in 3 studies
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.
Excerpt | Relevance | Reference |
---|---|---|
"Experimental allergic encephalomyelitis (EAE) is the animal model for multiple sclerosis." | 1.32 | Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. ( Banik, NL; Dasgupta, S; Jana, M; Pahan, K; Zhou, Y, 2003) |
"Leptin treatment had no effect on plasma lipid profile and glucose level." | 1.32 | Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. ( Bełtowski, J; Jamroz, A; Wójcicka, G, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dasgupta, S | 1 |
Zhou, Y | 1 |
Jana, M | 1 |
Banik, NL | 1 |
Pahan, K | 1 |
Bełtowski, J | 1 |
Wójcicka, G | 1 |
Jamroz, A | 1 |
Davis, BA | 1 |
Yu, PH | 1 |
Carlson, K | 1 |
O'Sullivan, K | 1 |
Boulton, AA | 1 |
3 other studies available for phenylacetic acid and Chronic Illness
Article | Year |
---|---|
Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps.
Topics: Acute Disease; Administration, Oral; Adoptive Transfer; Animals; Anti-Inflammatory Agents, Non-Stero | 2003 |
Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antimetabolites, Antineoplastic; Antioxidan | 2003 |
Plasma levels of phenylacetic acid, m- and p-hydroxyphenylacetic acid, and platelet monoamine oxidase activity in schizophrenic and other patients.
Topics: Antipsychotic Agents; Blood Platelets; Chronic Disease; Humans; Intellectual Disability; Monoamine O | 1982 |